Alembic Pharma gets USFDA nod for anti-seizure drug, stock volatile

• Alembic Pharmaceuticals received final USFDA approval for Lamotrigine Orally Disintegrating Tablets (25, 50, 100, 200 mg).
• The approved drug is therapeutically equivalent to GlaxoSmithKline LLC's Lamictal ODT.
• Lamotrigine is primarily used to treat seizures and has an estimated market size of $27 million by December 2025.
• It is indicated for various seizure types in patients aged two years and older, and for conversion to monotherapy in adults.
• The drug is also approved for maintenance treatment of bipolar I disorder to delay mood episodes.